Bosutinib Offers Long-Term Efficacy in CML Patients Who Failed TKI Therapy
According to a long-term follow-up analysis of a phase I/II trial, bosutinib provides durable responses and a favorable toxicity profile in patients with chronic phase CML who are resistant/intolerant to other tyrosine kinase inhibitors.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Lymphoma | Toxicology